IP Library Granted Patent US 9,228,174
Granted Patent B2
US 9,228,174 · App. 13/583,920 · Granted Jan 5, 2016

Mutated rep encoding sequences for use in AAV production

Inventors: Yvet Noordman (Amsterdam, NL); Jacek Lubelski (Amsterdam, NL); Andrew Christian Bakker (Amsterdam, NL)
Assignee: UNIQURE IP B.V.
C12N7/00C12N15/86C12N2710/14143C12N2750/14143C12N2750/14151C12N2800/105C12N2800/50C12N2800/90C12N2820/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,228,174
App. No.
13/583,920
Granted
Jan 5, 2016
Kind
B2
Abstract

Nucleic acids encoding Parvoviral Rep proteins with a mutated nuclear localization signal (NLS) are provided. Also provided is a nucleic acid comprising a nucleotide sequence encoding a Parvoviral Rep protein with a mutated zinc finger domain and a nucleic acid comprising a nucleotide sequence encoding a Parvoviral Rep protein comprising an amino acid mutation at position 43, 57, 79, 97, 120, 179, 305, 484, 493 or 571 with reference to SEQ ID NO: 2. Nucleic acid constructs and cells, such as insect cells, comprising the nucleic acids are provided as well as a method for producing a recombinant Parvoviral virion using the nucleic acids.

Claims (24)

1. A nucleic acid comprising a nucleotide sequence encoding a Parvoviral Rep protein, wherein a nuclear localization signal (NLS) in said Parvoviral Rep protein is mutated as compared with a corresponding wild type sequence by substitution of the codon encoding the amino acid at position 493 with a stop codon, said amino acid position being defined with reference to SEQ ID NO:1.

2. The nucleic acid according to claim 1 , further comprising a mutation of an amino acid at position 43, 79, 120, or 305 of the Parvoviral Rep protein in comparison to a corresponding wild type sequence, said amino acid position being defined with reference to SEQ ID NO: 2.

3. The nucleic acid according to claim 1 , comprising mutations of amino acids at positions: 43, 79, 120 and 493; 79, 120 and 493; or 79, 120, 305 and 493 in comparison with a corresponding wild type sequence, said amino acid position being defined with reference to SEQ ID NO: 2.

4. The nucleic acid according to claim 1 , wherein the Parvoviral Rep protein encoded by said nucleic acid has at least 80% sequence similarity to SEQ ID NO:2.

5. The nucleic acid according to claim 1 , wherein the parvoviral Rep protein is an adeno-associated virus (AAV) Rep protein.

6. A nucleic acid comprising the nucleotide sequence set out in any one of SEQ ID NOs: 13, 15, 17 or 19.

7. A nucleic acid comprising a nucleotide sequence encoding a Parvoviral Rep protein as set out in any one of SEQ ID NOs: 14, 16, 18, or 20.

8. A nucleic acid comprising two or more nucleotide sequences which encode a Parvoviral Rep protein, one or more of which is as according to claim 1 .

9. A Parvoviral Rep encoded by a nucleic acid as defined in claim 1 .

10. A nucleic acid construct comprising a nucleic acid according to claim 1 , wherein the said nucleic acid is operably linked to an expression control sequence for expression in an insect cell.

11. The nucleic acid construct according to claim 10 , wherein the nucleotide sequence is operably linked to a polyhedron promoter.

12. The nucleic acid construct according to claim 10 , wherein the construct is an insect cell-compatible vector.

13. An isolated insect cell comprising a nucleic acid according to claim 1 .

14. The insect cell according to claim 13 , wherein the insect cell further comprises:

a) a nucleic acid comprising at least one Parvoviral inverted terminal repeat (ITR) nucleotide sequence; and;

b) a nucleic acid sequence comprising a nucleotide sequence encoding Parvoviral capsid protein coding sequence operably linked to expression control sequences for expression in an insect cell.

15. The insect cell according to claim 13 , wherein the nucleic acids are comprised within one or more insect cell-compatible vectors.

16. The insect cell according to claim 13 , wherein the nucleic acid comprising at least one parvoviral inverted terminal repeat (ITR) nucleotide sequence further comprises at least one nucleotide sequence encoding a gene product of interest.

17. The insect cell according to claim 13 , wherein the Parvovirus is AAV.

18. A method for the production of a recombinant Parvoviral virion in an isolated insect cell, which method comprises:

a) culturing an isolated insect cell comprising a nucleic acid according to claim 12 under conditions such that a recombinant parvoviral virion is produced; and,

b) recovering the recombinant parvoviral virion.

19. The nucleic acid construct according to claim 12 , wherein the insect cell-compatible vector is a baculoviral vector.

20. The insect cell according to claim 15 , wherein the one or more insect cell-compatible vectors are baculoviral vectors.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 11, 2012
From: NOORDMAN, YVET; LUBELSKI, JACEK; BAKKER, ANDREW CHRISTIAN
To: UNIQURE IP B.V.
Reel/Frame 028937/0800 →
Continuity (2)
Provisional Application 61312845 · Mar 11, 2010
Related Publication 20130023034A1 · Jan 24, 2013